Published December 1, 2021
Prevention magazine included Thomas Russo, chief of infectious disease in the Jacobs School of Medicine and Biomedical Sciences in an article about which antibodies are working well – and not so well – against the Omicron variant. “The Eli Lilly and Regeneron monoclonal antibody treatments are directed against the spike protein of SARS-CoV-2, and Omicron has 32 mutations and a deletion in the spike protein,” Russo said. “Because of this, those treatments no longer bind with the virus.” The article was picked up by Yahoo! Life and MSN Canada.